University of California Irvine

BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity

Companies, academics, advocates push back on claims they should have disclosed genotype to Alzheimer's trial participants

BioCentury’s roundup of translational innovations

First program delivers an enzyme involved in the fatty acid synthesis pathway for patients with dry AMD

Perspectives from Diego Cadavid on Verge’s digital-first Phase Ib strategy for ALS, and on building a pivotal endpoint using an Xbox sensor

BioCentury’s roundup of translational innovations

Plus: Translational inhibition company Initial launches with $75M from ATP and updates from Biogen, Ascendis, Minerva, Teva-MedinCell, BMS, Avadel

Plus new CFO, CMO at Renibus, and updates from Bayer, Gilead, Shionogi and more

JHU spinout advancing COVID-19, ophthalmic programs based on hydroxyl dendrimer platform